This is a repository copy of *Hypoglycaemia in a patient with a solitary fibrous tumour*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/130822/

Version: Published Version

**Article:**
Okpe, A., Ramsay, K., Fernando, I.P. et al. (2 more authors) (2016) *Hypoglycaemia in a patient with a solitary fibrous tumour*. European Journal of Case Reports in Internal Medicine, 3 (3). ISSN 2284-2594

10.12890/2016_000353

© EFIM 2016. This article is licensed under a Commons Attribution Non-Commercial 4.0 License. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

**Reuse**
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative works on the same terms. More information and the full terms of the licence here:
https://creativecommons.org/licenses/

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Hypoglycaemia in a Patient with a Solitary Fibrous Tumour

Andrew Okpe, Kerri Ramsay, Isuru P Fernando, Emily Mudenha, Devaka JS Fernando
Department of Diabetes and Endocrinology, King's Mill Hospital, Sutton-in-Ashfield, Nottinghamshire, UK

Received: 05/12/2015
Accepted: 31/01/2016
Published: 07/03/2016

How to cite this article: Okpe A, Ramsay K, Fernando IP, Mudenha E, Fernando DJS. Hypoglycaemia in a patient with a solitary fibrous tumour. EJCRIM 2016;3:doi:10.12890/2016_000353

Conflicts of Interests: The authors declare that there are no competing interests.

This article is licensed under a Commons Attribution Non-Commercial 4.0 License

ABSTRACT
Objective: To illustrate an unusual mechanism causing hypoglycaemia.

Material and methods: A 76-year-old man presented with episodes of agitation and confusion and was resuscitated with oral glucose gel when found to be hypoglycaemic.

Results: A CT scan for an abdominal mass confirmed a solitary fibrous tumour (SFT). The sarcoma multidisciplinary team suggested conservative management. The patient's episodic hypoglycaemia was managed with diet modification including corn-based starch, scheduled snacks and dexamethasone. Glucose levels were within normal range at discharge from hospital. The patient was referred to the palliative care team for follow-up.

Conclusion: SFTs causing non-islet cell tumour hypoglycaemia are difficult to treat.

LEARNING POINTS
• To be aware of rarer causes of hypoglycaemia and to consider unusual causes in acute presentations of hypoglycaemia, especially in patients who do not have diabetes.
• This case illustrates the importance of a thorough general physical and systemic examination, as identifying the abdominal mass is essential to the early diagnosis of this rare condition.
• Solitary fibrous tumours causing non-islet cell tumour hypoglycaemia are difficult to treat, and even when surgical resections are applicable, recurrence rates are high.

KEYWORDS
Hypoglycaemia; non insulin mediated hypoglycaemia; insulin-like growth factor, solitary fibrous tumour, retroperitoneal tumour.

INTRODUCTION
Spontaneous hypoglycaemia may be caused by insulin secreted from a functional tumour of the pancreatic islet cells, hypoadrenalism, hypopituitarism or liver pathology. Hypoinsulinaemic hypoglycaemia as a paraneoplastic syndrome (non-islet cell tumour hypoglycaemia, NICTH) is a rare complication of some tumours[1]. Excessive production of insulin-like growth factor-2 (IGF-2) by the tumour cells stimulates insulin receptors and increased glucose use. If this rare syndrome is not suspected, it may be life-threatening and may lead to cerebral hypoxia and death. We report the case of a patient with NICTH caused by a solitary fibrous tumour (SFT).
CASE REPORT
A 76-year-old male ex-miner presented to the emergency assessment unit with agitation and confusion and a blood glucose level of 2.1 mmol/l. There was a history of a weight loss of 5–8 kg within the previous 6 months. His past medical history included hypertension, benign prostatic hypertrophy, left shoulder hemiarthroplasty, osteoarthritis and age-related macular degeneration. He had no significant family history of illness.

On examination he was afebrile and euvoalaemic after the paramedics had resuscitated him with intravenous dextrose. There was an intra-abdominal smooth, non-tender, non-ballotable right upper quadrant mass on examination.

During his hospital stay, the patient had multiple episodes of hypoglycaemia that were managed with intravenous dextrose, oral dextrose gel, dexamethasone, corn-based starch in additional to meals, and frequent scheduled snacks as suggested by the dieticians.

The CT scan and abdominal angiogram showed a heterogeneous mass measuring 26×15×18 cm and with calcification, in the right upper retroperitoneum between the liver and right kidney (Fig. 1). The lesion had a rich blood supply from the branches of the right renal artery and directly from the aorta superior to the right renal artery. There was possible inferior venacaval invasion. There was confluent mediastinal lymphadenopathy of uncertain significance.

Histology of the core biopsy showed a monomorphic spindle cell tumour with stromal ropey collagen. The expression of CD34 and BCL2, and lack of other significant markers (CD117, DOG1, AE1/AE3, EMA, S100, Melan A, desmin and CD31) confirmed the diagnosis of SFT. There was no cellular atypia, >3 mitoses per 10 high-power fields (hpf) or necrosis to suggest a definitive diagnosis of a malignant SFT.

SFTs are categorised as tumours with intermediate biological potential but where the biological behaviour of individual tumours is notoriously difficult to predict. Tumours ≥15 cm in diameter in patients ≤55 years of age and with ≥4 mitotic figures per 10 hpf have been shown to be associated with a high risk of both metastasis and death[2]. With the rich blood supply precluding tumour chemo-embolisation and surgical intervention, the sarcoma multidisciplinary team concluded that the general outcome in this patient was likely to be poor.

Table 1 tabulates the laboratory results when the patient was euglycaemic. The low-normal proinsulin levels exclude the possibility of ectopic insulin secretion, insulinoma or exogenous insulin administration as the cause of hypoglycaemia. The raised IGF-2 levels confirm that this patient had Doege-Potter syndrome[3].

Plasma proinsulin levels, cortisol, IGF-1 and IGF-2 levels were also investigated.

The patient’s episodic hypoglycaemia was managed with diet modification including corn-based starch, scheduled snacks and dexamethasone. He responded well to the treatment without further episodes of hypoglycaemia. The patient was stabilised on dexamethasone and discharged with a glucagon pen and counselling to be followed up by the palliative team.
DISCUSSION

NICTH linked with excessive production of IGFs and Doege-Potter syndrome\textsuperscript{20} was first reported in a patient with a spindle cell tumour with hypoglycaemia of unknown aetiology. The pathogenesis of NICTH appears to be incompletely processed IGF-2 (‘big’ IGF). IGF-2 leads to increased skeletal muscle glucose use, suppression of glucagon, growth hormone release and inhibition of hepatic glucose release, with resulting persistent chronic hypoglycaemia. It also has higher affinity for insulin receptors and lower affinity for insulin binding proteins (IGF-BP)\textsuperscript{4}, mimicking the action of insulin. The IGF-2:IGF-1 ratio of 16 (normal=3:1) in our patient is pathognomonic of NICTH as the cause of hypoglycaemia\textsuperscript{4}.

The aims of treatment in patients with NICTH include maintaining euglycaemia and where possible, curative excision of the IGF-2 producing tumour (IGF-2oma). Simple measures such as administration of glucose tablets or liquid, fruit juice or intravenous glucose can be used in the acute setting. The usual medical management for spontaneous hypoglycaemia in instances of insulinomas (which includes diazoxide, octreotide and glucagon) has some limited use in NICTH, but steroids are the mainstay of treatment. Steroids decrease the amount of ‘big’ IGF-2 by converting pre-pro IGF into IGF-2. They also re-establish the normal IGF:IGF-BP ratio. Supra-physiological doses of recombinant growth hormone increase IGF-BP, preventing interaction with insulin receptors and ultimately decreasing the chances of hypoglycaemia\textsuperscript{5}.

Definitive treatment depends on the nature of the tumour. If the tumour is resectable, surgery is often curative. The metabolic alterations caused by NICTH are reversible in many patients after complete surgical excision of ‘big’ IGF-2 producing tumours. A search of the literature from 2004 to 2014 revealed around 58 IGF-2oma case reports, 21 which were SFTs (both malignant and benign). Chemotherapy, embolisation or irradiation may also be considered with a variable success rate in controlling hypoglycaemia.

\begin{table}[h]
\centering
\begin{tabular}{|l|l|l|}
\hline
Test & Result & Reference range \\
\hline
Glucose & 8 mmol/l & 3.0–6.0 \\
Proinsulin & 3 pmol/l & 0–10 \\
Insulin-like growth factor-1 (IGF-1) & 7.7 nmol/l & <9 \\
Insulin-like growth factor-2 (IGF-2) & 123.5 nmol/l & <20 \\
IGF-2:IGF-1 & 16.0 & <10 \\
Cortisol & 229 nmol/l & 140–690 \\
\hline
\end{tabular}
\caption{Laboratory results.}
\end{table}

REFERENCES